Denmark's ALK-Abello Q4 revenue rises 17% on higher tablet sales

Alk-Abello A/S

20/02/2026 06:26

Overview

Denmark allergy treatment firm's Q4 revenue rose 17% to DKK 1,733 mln

Q4 EBIT increased 88% to DKK 387 mln, reflecting planned growth investments

Company proposes DKK 355 mln dividend for 2025, about 30% of net profit

Outlook

ALK expects 2026 revenue growth of 11-15% in local currencies

Company projects 2026 EBIT margin around 25%

Growth driven by increased patient treatment with AIT and anaphylaxis products

Result Drivers

TABLET SALES - Tablet sales increased by 15% to DKK 910 mln, driven by expanding patient and prescriber bases in Europe and North America

ANAPHYLAXIS PRODUCTS - Sales of anaphylaxis and other products rose 50% to DKK 216 mln, driven by Jext and neffy

GROWTH INVESTMENTS - Operating profit increased 88% to DKK 387 mln, reflecting planned growth investments

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
DKK 1.73 bln
Q4 EBIT
DKK 387 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for ALK-Abello A/S is DKK257.50, about 17% above its February 19 closing price of DKK220.00

The stock recently traded at 34 times the next 12-month earnings vs. a P/E of 34 three months ago

Press Release: ID:nGNE61ybwJ

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)